Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Health Catalyst (HCAT) EBITDA Margin (2018 - 2026)

Health Catalyst filings provide 9 years of EBITDA Margin readings, the most recent being 144.83% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 12396.0% to 144.83% in Q1 2026 year-over-year; TTM through Mar 2026 was 76.62%, a 5925.0% decrease, with the full-year FY2025 number at 46.88%, down 2828.0% from a year prior.
  • EBITDA Margin hit 144.83% in Q1 2026 for Health Catalyst, down from 109.91% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 13.87% in Q3 2024 to a low of 144.83% in Q1 2026.
  • Median EBITDA Margin over the past 5 years was 39.54% (2023), compared with a mean of 44.17%.
  • Biggest five-year swings in EBITDA Margin: soared 3338bps in 2023 and later plummeted -12396bps in 2026.
  • Health Catalyst's EBITDA Margin stood at 48.5% in 2022, then increased by 18bps to 39.54% in 2023, then surged by 55bps to 17.84% in 2024, then crashed by -516bps to 109.91% in 2025, then plummeted by -32bps to 144.83% in 2026.
  • The last three reported values for EBITDA Margin were 144.83% (Q1 2026), 109.91% (Q4 2025), and 17.96% (Q3 2025) per Business Quant data.